600056 中国医药
已收盘 04-30 15:00:00
资讯
新帖
简况
中国医药（600056）2026年一季报简析：净利润同比增长5.58%，盈利能力上升
证券之星 · 06:02
中国医药（600056）2026年一季报简析：净利润同比增长5.58%，盈利能力上升
中国医药（600056）披露2026年第一季度报告全文，4月28日股价上涨0.1%
证券之星 · 04-28 22:24
中国医药（600056）披露2026年第一季度报告全文，4月28日股价上涨0.1%
图解中国医药一季报：第一季度单季净利润同比增长5.58%
证券之星 · 04-28 19:29
图解中国医药一季报：第一季度单季净利润同比增长5.58%
股市必读：中国医药年报 - 第四季度单季净利润同比下降82.53%
证券之星 · 04-27
股市必读：中国医药年报 - 第四季度单季净利润同比下降82.53%
中国医药(600056)3月31日股东户数12.9万户，较上期减少1.83%
证券之星 · 04-25
中国医药(600056)3月31日股东户数12.9万户，较上期减少1.83%
图解中国医药年报：第四季度单季净利润同比下降82.53%
证券之星 · 04-25
图解中国医药年报：第四季度单季净利润同比下降82.53%
小摩：中国医药板块获利回吐 为良好入场良机
智通财经网 · 04-24
小摩：中国医药板块获利回吐 为良好入场良机
中国医药最新公告：子公司获得注射用尼可地尔药品注册证书
证券之星 · 04-20
中国医药最新公告：子公司获得注射用尼可地尔药品注册证书
每周股票复盘：中国医药（600056）完成10亿公司债发行
证券之星 · 04-19
每周股票复盘：中国医药（600056）完成10亿公司债发行
中国医药（600056）披露2026年面向专业投资者公开发行公司债券（第一期）发行结果，4月17日股价下跌1.74%
证券之星 · 04-17
中国医药（600056）披露2026年面向专业投资者公开发行公司债券（第一期）发行结果，4月17日股价下跌1.74%
中国医药新注册《营销数据管理软件V1.0》项目的软件著作权
证券之星 · 04-16
中国医药新注册《营销数据管理软件V1.0》项目的软件著作权
异动快报：中国医药（600056）4月3日11点15分触及涨停板
证券之星 · 04-03
异动快报：中国医药（600056）4月3日11点15分触及涨停板
每周股票复盘：中国医药（600056）子公司获注射用硫酸艾沙康唑药品注册
证券之星 · 03-22
每周股票复盘：中国医药（600056）子公司获注射用硫酸艾沙康唑药品注册
中国医药新注册《投标业务备案软件V1.0》项目的软件著作权
证券之星 · 03-19
中国医药新注册《投标业务备案软件V1.0》项目的软件著作权
中国医药(600056.SH)：注射用硫酸艾沙康唑获得药品注册证书
智通财经 · 03-17
中国医药(600056.SH)：注射用硫酸艾沙康唑获得药品注册证书
每周股票复盘：中国医药（600056）子公司获米诺地尔搽剂上市许可
证券之星 · 03-08
每周股票复盘：中国医药（600056）子公司获米诺地尔搽剂上市许可
中国医药（600056）披露子公司获得米诺地尔搽剂药品补充申请批准通知书，3月5日股价上涨0.58%
证券之星 · 03-05
中国医药（600056）披露子公司获得米诺地尔搽剂药品补充申请批准通知书，3月5日股价上涨0.58%
每周股票复盘：中国医药（600056）子公司获药品注册证书
证券之星 · 03-01
每周股票复盘：中国医药（600056）子公司获药品注册证书
中国医药（600056）披露为控股公司提供担保公告，2月27日股价上涨0.28%
证券之星 · 02-27
中国医药（600056）披露为控股公司提供担保公告，2月27日股价上涨0.28%
中国医药（600056）披露子公司获得注射用磷酸特地唑胺药品注册证书，2月25日股价上涨0.47%
证券之星 · 02-25
中国医药（600056）披露子公司获得注射用磷酸特地唑胺药品注册证书，2月25日股价上涨0.47%
加载更多
公司概况
公司名称：
中国医药健康产业股份有限公司
所属行业：
批发业
上市日期：
1997-05-15
主营业务：
中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是化学制剂、诊断药品及试剂、医用耗材、医疗器械、特医产品、医美产品、中成药、中药饮片、配方颗粒、生物制剂、营养保健品。
发行价格：
7.02
{"stockData":{"symbol":"600056","market":"SH","secType":"STK","nameCN":"中国医药","latestPrice":10.36,"timestamp":1777532400000,"preClose":10.4,"halted":0,"volume":11806149,"delay":0,"changeRate":-0.0038,"floatShares":1495000000,"shares":1496000000,"eps":0.327,"marketStatus":"已收盘","change":-0.04,"latestTime":"04-30 15:00:00","open":10.38,"high":10.41,"low":10.32,"amount":122000000,"amplitude":0.0087,"askPrice":10.36,"askSize":211,"bidPrice":10.35,"bidSize":2536,"shortable":0,"etf":0,"ttmEps":0.327,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":10.4,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":11.44,"lowLimit":9.36,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1495879748,"isCdr":false,"pbRate":1.29,"roa":"--","peRate":31.681957,"roe":"1.53%","epsLYR":0.3164,"committee":0.607903,"marketValue":15497000000,"turnoverRate":0.0079,"status":1,"floatMarketCap":15492000000},"requestUrl":"/m/hq/s/600056","defaultTab":"news","newsList":[{"id":"2631527675","title":"中国医药（600056）2026年一季报简析：净利润同比增长5.58%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2631527675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631527675?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:02","pubTimestamp":1777500178,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期中国医药发布2026年一季报。截至本报告期末，公司营业总收入81.89亿元，同比下降3.97%，归母净利润1.82亿元，同比上升5.58%。本报告期中国医药盈利能力上升，毛利率同比增幅0.14%，净利率同比增幅5.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000018405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630585536","title":"中国医药（600056）披露2026年第一季度报告全文，4月28日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630585536","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630585536?lang=zh_cn&edition=full","pubTime":"2026-04-28 22:24","pubTimestamp":1777386250,"startTime":"0","endTime":"0","summary":"截至2026年4月28日收盘，中国医药报收于10.28元，较前一交易日上涨0.1%，最新总市值为153.78亿元。该股当日开盘10.21元，最高10.38元，最低10.2元，成交额达1.26亿元，换手率为0.82%。近日，中国医药发布《2026年第一季度报告全文》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800065270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0188","BK0082","BK0028","BK0185","BK0010","600056","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630306106","title":"图解中国医药一季报：第一季度单季净利润同比增长5.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630306106","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630306106?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:29","pubTimestamp":1777375797,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药2026年一季报显示，一季度公司主营收入81.89亿元，同比下降3.97%；归母净利润1.82亿元，同比上升5.58%；扣非净利润1.77亿元，同比上升9.97%；负债率61.04%，投资收益761.53万元，财务费用2944.25万元，毛利率10.61%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800055456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630337394","title":"股市必读：中国医药年报 - 第四季度单季净利润同比下降82.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630337394","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630337394?lang=zh_cn&edition=full","pubTime":"2026-04-27 08:21","pubTimestamp":1777249276,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日中国医药披露，截至2026年3月31日公司股东户数为12.9万户，较12月31日减少2401.0户，减幅为1.83%。公司公告汇总2025年年度报告摘要中国医药健康产业股份有限公司2025年年度报告摘要显示，公司2025年实现营业收入35,361,621,734.95元，同比增长0.34%；归属于上市公司股东的净利润为473,229,055.14元，同比下降18.77%；扣除非经常性损益后的净利润为376,478,717.77元，同比增长16.49%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700007574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630708668","title":"中国医药(600056)3月31日股东户数12.9万户，较上期减少1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630708668","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630708668?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:02","pubTimestamp":1777107763,"startTime":"0","endTime":"0","summary":"证券之星消息，近日中国医药披露，截至2026年3月31日公司股东户数为12.9万户，较12月31日减少2401.0户，减幅为1.83%。在医药商业行业个股中，中国医药股东户数高于行业平均水平，截至3月31日，医药商业行业平均股东户数为4.58万户。从股价来看，2025年12月31日至2026年3月31日，中国医药区间跌幅为0.58%，在此期间股东户数减少2401.0户，减幅为1.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500031848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0028","BK0188","BK0082","BK0010","600056","BK0185","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630294598","title":"图解中国医药年报：第四季度单季净利润同比下降82.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630294598","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630294598?lang=zh_cn&edition=full","pubTime":"2026-04-25 01:15","pubTimestamp":1777050919,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药2025年年报显示，当年度公司主营收入353.62亿元，同比上升0.34%；归母净利润4.73亿元，同比下降18.77%；扣非净利润3.76亿元，同比上升16.49%；其中2025年第四季度，公司单季度主营收入94.67亿元，同比上升12.26%；单季度归母净利润1846.51万元，同比下降82.53%；单季度扣非净利润-1793.72万元，同比上升79.01%；负债率61.04%，投资收益-6801.02万元，财务费用1.1亿元，毛利率10.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500003740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629811562","title":"小摩：中国医药板块获利回吐 为良好入场良机","url":"https://stock-news.laohu8.com/highlight/detail?id=2629811562","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629811562?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:52","pubTimestamp":1777020733,"startTime":"0","endTime":"0","summary":"该行认为昨日生科股医药股回调，是建立中国医疗保健配置以迎接下一波催化剂驱动上涨行情的良好进场时机。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260424/20260424164629_20525.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260424/20260424164629_20525.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1162221912.USD","JPO","LU2456880835.USD","LU1116320901.HKD","LU1720051017.SGD","BK4504","600056","LU2552382058.USD","BK0010","LU2054465674.USD","LU1366192091.USD","LU0070302665.USD","IE00BZ1G4Q59.USD","LU2430703095.HKD","IE00BLSP4452.SGD","LU2023250330.USD","LU2505996681.GBP","LU1280957306.USD","IE00BBT3K403.USD","IE00BDCRKT87.USD","LU0251132253.USD","LU2236285917.USD","LU1974910355.USD","LU1267930490.SGD","LU2552382132.HKD","LU1988902786.USD","LU1670627923.USD","BK4516","LU0203345920.USD","LU0496365809.HKD","LU2237443465.HKD","LU0106261372.USD","LU1244550577.SGD","LU0320765646.SGD","IE00BLSP4239.USD","LU0689472784.USD","LU0006306889.USD","LU0106831901.USD","LU2242649171.HKD","LU0170899867.USD","LU0208291251.USD","BK4533","LU0211326839.USD","LU0238689110.USD","LU2237443978.SGD","LU0323591593.USD","LU0211328371.USD","LU0211326755.USD","LU1244550494.USD","JPMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628745479","title":"中国医药最新公告：子公司获得注射用尼可地尔药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628745479","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628745479?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:13","pubTimestamp":1776676396,"startTime":"0","endTime":"0","summary":"中国医药公告称，公司下属全资子公司天方药业近日收到国家药监局核准签发的两份注射用尼可地尔《药品注册证书》。该药品主要用于治疗急性心力衰竭和不稳定型心绞痛，国内已有42家生产企业获得批件。截至公告披露日，该药品累计投入约808万元。数据显示，2024年中国三大终端六大市场该药品销售额约为6.21亿元，2025年前三季度约为2.18亿元。本次获证将进一步夯实公司原料制剂一体化发展战略，有利于丰富公司产品线矩阵，完善产品布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600056","BK0082","BK0188","BK0185","BK0028","BK0250","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628075611","title":"每周股票复盘：中国医药（600056）完成10亿公司债发行","url":"https://stock-news.laohu8.com/highlight/detail?id=2628075611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628075611?lang=zh_cn&edition=full","pubTime":"2026-04-19 01:48","pubTimestamp":1776534492,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，中国医药报收于10.7元，较上周的10.97元下跌2.46%。本周，中国医药4月15日盘中最高价报11.21元。本周关注点公司公告汇总：中国医药完成10亿元公司债发行，票面利率1.78%，认购倍数4.61倍公司公告汇总中国医药健康产业股份有限公司于2026年4月17日完成2026年面向专业投资者公开发行公司债券（第一期）的发行工作。本次发行经中国证监会注册批准，注册额度不超过20亿元，可在24个月内分期发行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0175","BK0188","BK0250","BK0028","600056","BK0185","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628108202","title":"中国医药（600056）披露2026年面向专业投资者公开发行公司债券（第一期）发行结果，4月17日股价下跌1.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628108202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628108202?lang=zh_cn&edition=full","pubTime":"2026-04-17 22:09","pubTimestamp":1776434957,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，中国医药报收于10.7元，较前一交易日下跌1.74%，最新总市值为160.06亿元。该股当日开盘10.8元，最高10.82元，最低10.66元，成交额达3.07亿元，换手率为1.92%。近日，中国医药健康产业股份有限公司披露《关于2026年面向专业投资者公开发行公司债券（第一期）发行结果的公告》。公司董事、高管、持股5%以上股东及关联方未参与认购。本次发行经中国证监会注册批准，注册额度不超过20亿元，可在24个月内分期发行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700045554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0082","600056","BK0185","BK0175","BK0250","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627423466","title":"中国医药新注册《营销数据管理软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2627423466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627423466?lang=zh_cn&edition=full","pubTime":"2026-04-16 01:56","pubTimestamp":1776275776,"startTime":"0","endTime":"0","summary":"证券之星消息，近日中国医药（600056）新注册了《营销数据管理软件V1.0》项目的软件著作权。今年以来中国医药新注册软件著作权6个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了6562.9万元，同比增3.06%。通过天眼查大数据分析，中国医药健康产业股份有限公司共对外投资了29家企业，参与招投标项目811次；财产线索方面有商标信息5条，专利信息4条，著作权信息5条；此外企业还拥有行政许可16个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600002353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0250","600056","BK0082","BK0028","BK0175","BK0010","159180","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624634591","title":"异动快报：中国医药（600056）4月3日11点15分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2624634591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624634591?lang=zh_cn&edition=full","pubTime":"2026-04-03 11:20","pubTimestamp":1775186426,"startTime":"0","endTime":"0","summary":"证券之星4月3日盘中消息，11点15分中国医药（600056）触及涨停板。其所属行业医药商业目前上涨。领涨股为重药控股。该股为医药商业，脑科学，健康中国概念热股。4月2日的资金流向数据方面，主力资金净流出3679.57万元，占总成交额15.03%，游资资金净流入915.02万元，占总成交额3.74%，散户资金净流入2764.55万元，占总成交额11.3%。近5日资金流向一览见下表：中国医药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300018223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0185","BK0188","BK0010","BK0175","BK0028","BK0082","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621964337","title":"每周股票复盘：中国医药（600056）子公司获注射用硫酸艾沙康唑药品注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2621964337","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621964337?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:09","pubTimestamp":1774116550,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，中国医药报收于10.22元，较上周的10.59元下跌3.49%。本周，中国医药3月17日盘中最高价报10.64元。中国医药当前最新总市值152.88亿元，在医药商业板块市值排名6/32，在两市A股市值排名1310/5190。截至目前，国内已有包括三洋药业在内的17家生产企业获批该药品注册。2024年该药品在中国三大终端六大市场销售额约为1.62亿元，2025年前三季度约为2.41亿元。此次获批有助于丰富公司产品线，但未来销售存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600056","BK0082","BK0188","BK0185","BK0028","BK0250","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620266788","title":"中国医药新注册《投标业务备案软件V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2620266788","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620266788?lang=zh_cn&edition=full","pubTime":"2026-03-19 02:16","pubTimestamp":1773857774,"startTime":"0","endTime":"0","summary":"证券之星消息，近日中国医药（600056）新注册了《投标业务备案软件V1.0》项目的软件著作权。今年以来中国医药新注册软件著作权1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了6562.9万元，同比增3.06%。通过天眼查大数据分析，中国医药健康产业股份有限公司共对外投资了29家企业，参与招投标项目795次；财产线索方面有商标信息5条，专利信息4条；此外企业还拥有行政许可16个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900001176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0010","BK0185","BK0082","BK0028","BK0175","BK0188","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620544400","title":"中国医药(600056.SH)：注射用硫酸艾沙康唑获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2620544400","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620544400?lang=zh_cn&edition=full","pubTime":"2026-03-17 16:25","pubTimestamp":1773735902,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国医药(600056.SH)发布公告，近日，公司下属全资子公司海南通用三洋药业有限公司(以下简称“三洋药业”)收到国家药品监督管理局(以下简称“国家药监局”)核准签发的注射用硫酸艾沙康唑《药品注册证书》。本次三洋药业获得该药品注册证书，有利于丰富公司产品线，同时为公司后续仿制药开发积累了宝贵的经验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国医药(600056.SH)：注射用硫酸艾沙康唑获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0028","BK0082","BK0250","600056","BK0188","BK0185","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617750668","title":"每周股票复盘：中国医药（600056）子公司获米诺地尔搽剂上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2617750668","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617750668?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:22","pubTimestamp":1772907733,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，中国医药报收于10.49元，较上周的10.66元下跌1.59%。本周，中国医药3月3日盘中最高价报10.65元。本周关注点公司公告汇总：子公司天方药业获米诺地尔搽剂上市许可持有人变更批准。公司公告汇总中国医药全资子公司天方药业有限公司收到国家药监局核准签发的两份米诺地尔搽剂《药品补充申请批准通知书》，药品上市许可持有人由海南广升誉制药有限公司变更为天方药业。截至公告日，项目累计投入约645万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0185","BK0028","BK0188","BK0175","BK0250","BK0010","BK0082","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617252545","title":"中国医药（600056）披露子公司获得米诺地尔搽剂药品补充申请批准通知书，3月5日股价上涨0.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617252545","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617252545?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:36","pubTimestamp":1772721376,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，中国医药报收于10.38元，较前一交易日上涨0.58%，最新总市值为155.27亿元。该股当日开盘10.4元，最高10.42元，最低10.35元，成交额达9035.94万元，换手率为0.58%。近日，中国医药发布公告称，其全资子公司天方药业有限公司收到国家药监局核准签发的两份米诺地尔搽剂《药品补充申请批准通知书》，该药品上市许可持有人由海南广升誉制药有限公司变更为天方药业。国内已有58家生产企业获批该药品，2024年全国销售额约4.47亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500039620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","600056","BK0010","BK0188","BK0175","BK0185","BK0028","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843481","title":"每周股票复盘：中国医药（600056）子公司获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843481","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843481?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:13","pubTimestamp":1772302390,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，中国医药报收于10.66元，较上周的10.55元上涨1.04%。本周关注点公司公告汇总：子公司获注射用磷酸特地唑胺药品注册证书公司公告汇总：为控股公司江西南华提供10,000万元担保公司公告汇总关于子公司获得药品注册证书的公告中国医药全资子公司海南通用康力制药有限公司近日收到国家药监局核准签发的注射用磷酸特地唑胺《药品注册证书》。国家药监局于2024年9月受理该药品注册申请，截至目前累计投入约1274万元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0188","BK0175","600056","BK0010","BK0185","BK0082","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614852427","title":"中国医药（600056）披露为控股公司提供担保公告，2月27日股价上涨0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614852427","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614852427?lang=zh_cn&edition=full","pubTime":"2026-02-27 22:49","pubTimestamp":1772203750,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，中国医药报收于10.66元，较前一交易日上涨0.28%，最新总市值为159.46亿元。该股当日开盘10.61元，最高10.67元，最低10.57元，成交额达1.14亿元，换手率为0.72%。近日，中国医药健康产业股份有限公司发布《关于为控股公司提供担保的公告》。公司持有南华通用49%股权，表决权比例为51%，南华通用为公司控股子公司。截至公告日，公司及其控股子公司对外担保总额为30,000万元，占公司最近一期经审计净资产的2.54%，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700042758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0175","BK0188","BK0250","BK0028","600056","BK0185","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614284035","title":"中国医药（600056）披露子公司获得注射用磷酸特地唑胺药品注册证书，2月25日股价上涨0.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614284035","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614284035?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:49","pubTimestamp":1772030948,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，中国医药报收于10.67元，较前一交易日上涨0.47%，最新总市值为159.61亿元。该股当日开盘10.63元，最高10.73元，最低10.61元，成交额达1.04亿元，换手率为0.65%。中国医药近日披露公告，其全资子公司海南通用康力制药有限公司近日收到国家药监局核准签发的注射用磷酸特地唑胺《药品注册证书》。国家药监局于2024年9月受理该药品注册申请，截至目前累计投入约1274万元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0250","BK0028","BK0082","BK0175","BK0188","BK0185","600056"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777546908213,"stockEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0136},{"period":"3month","weight":-0.058},{"period":"6month","weight":-0.078},{"period":"1year","weight":0.0409},{"period":"ytd","weight":0.0068}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"中国医药健康产业股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"129001人(较上一季度减少1.83%)","perCapita":"11591股","listingDate":"1997-05-15","address":"北京市丰台区西营街1号院1区1号楼25-28层","registeredCapital":"149587万元","survey":" 中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是化学制剂、诊断药品及试剂、医用耗材、医疗器械、特医产品、医美产品、中成药、中药饮片、配方颗粒、生物制剂、营养保健品。","listedPrice":7.02},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国医药,600056,中国医药股票,中国医药股票老虎,中国医药股票老虎国际,中国医药行情,中国医药股票行情,中国医药股价,中国医药股市,中国医药股票价格,中国医药股票交易,中国医药股票购买,中国医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}